Celentyx Ltd enters into agreement with Meija Seika Kaisha, Ltd. to discover new development path for Meiji drug candidates

25-Aug-2009 - United Kingdom

Celentyx Ltd announced that it has entered into a drug reprofiling agreement with Meiji Seika Kaisha, Ltd to seek alternative development paths for Meiji drug candidates using an application of the Immuno-Profiling platform™ called Novel Clinical Indication Profiling™ (NCIP™). These drug candidates were previously discontinued or de-prioritized for reasons other than safety.

Professor Nicholas Barnes, CEO of Celentyx Ltd, said, "We are particularly pleased to add Meiji as a partner since they have a number of candidate drugs impacting a target that we have identified on key cell subsets within the human immune system. Celentyx’s NCIP™ provides an efficient evaluation of a drug’s ability to signal responses in human immune cells with exceptionally high resolution to determine the therapeutic potential of small molecules and biologicals. Our goal is to provide partners with substantial value and revive development paths for drugs that retain potential for immune system disorders."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances